Fc-Modified IgG for Local CNS Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Systemically administered IL-12 for brain tumor treatment results in severe adverse events due to high systemic levels of interferon-γ, and existing local delivery methods fail to prevent systemic leakage and export across the blood-brain barrier, necessitating a solution to enhance tissue retention and reduce systemic accumulation.
Innovation Solution
A modified Fc region of IgG with mutations I253N and H435Q, reducing affinity to the neonatal Fc receptor (FcRn), is used in a fusion polypeptide with IL-12 for local intracranial delivery, enhancing brain retention and minimizing systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If IL-12 is administered systemically for brain tumor treatment, then anti-tumor effect is achieved, but severe adverse events occur due to high systemic levels of interferon-γ
Solution Approach 1:
The patent segments the delivery system by using local intracranial injection to deliver IL-12 directly to the brain tumor site, separating the treatment effect (localized to brain) from systemic circulation. This spatial segmentation prevents systemic toxic side effects while maintaining high local concentration of IL-12 at the tumor site.
Solution Approach 2:
The patent introduces an Fc-modified polypeptide as an intermediary carrier that binds IL-12 and delivers it to the brain. The Fc region with reduced FcRn affinity acts as a mediator that controls the pharmacokinetics of IL-12, enabling localized delivery while minimizing systemic exposure and associated toxic effects.
2Quantity of substance
If local intracranial delivery is used to achieve high IL-12 concentration in the brain, then tissue retention is improved, but systemic leakage and export across the blood-brain barrier occur
Solution Approach 1:
The patent changes the molecular parameters of the IL-12 carrier by modifying the Fc region with specific mutations (I253N, H435Q, and/or N434S) that alter the affinity for FcRn. This parameter change in FcRn binding affinity reduces active export across the blood-brain barrier and minimizes systemic leakage, thereby improving brain tissue retention of IL-12.
3Quantity of substance
If Fc region is modified to reduce FcRn affinity, then brain retention is enhanced and systemic accumulation is reduced, but pharmacostability and bioavailability may be affected
Solution Approach 1:
The patent applies local quality modification by introducing specific point mutations (I253N, H435Q, N434S) at particular locations in the Fc region. These localized changes selectively reduce FcRn affinity without compromising the overall structural integrity and pharmacostability of the Fc fusion protein, thereby achieving improved brain retention while maintaining reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Fc region significantly decreases the serum-to-brain concentration ratio of IL-12, allowing for high local concentrations in the brain while minimizing systemic toxic side effects, thereby improving the therapeutic window and tissue retention.
Implementation Method 1
The Fc region bears a modification resulting in reduced affinity to the neonatal Fc receptor (FcRn)... FcRn is also active in endothelial cells and in red pulp macrophages, where it prevents degradation and prolongs serum half-life live of Fc containing molecules
Data Source
AI summary
A polypeptide comprising a crystallizable fragment (Fe) region of IgG for use in prevention or treatment of a disease, in particular of a disease affecting the central nervous system. The polypeptide is administered locally to compartments, in particular to the central nervous system. The Fe region comprises the mutations I253N and H435Q and an H at position 310 resulting in reduced affinity to the neonatal Fe receptor (FeRn), resulting in an increased brain to serum concentration of the polypeptide.